Sizhen Wang made a non binding proposal to acquire the remaining 49.2% stake in Genetron Holdings Limited from Genetron Health (Hong Kong) Company Limited and others for $60 million.

Sizhen Wang made a non binding proposal to acquire the remaining 49.2% stake in Genetron Holdings Limited (NasdaqGM:GTH) from Genetron Health (Hong Kong) Company Limited and others for $60 million on August 21, 2022. The deal will be funded by a mix of debt and rollover equity capital by third party sponsors. A special committee consisting Wing Kee Lau and Dian Kang has been formed to evaluate and consider the Proposed Transaction as well as other potential strategic alternatives.

The Special Committee intends to retain advisors, including an independent financial advisor and independent legal counsel, to assist it in its evaluation. Kroll, LLC is acting as independent financial advisor and Davis Polk & Wardwell LLP as its independent legal counsel to Genetron Holdings Limited.